Halozyme Therapeutics, Inc. (HALO)
Valor JustoFundamental
70
Precio
$108.56
Capitalización Bursátil
$12.53B
Parte 1 · Cuánto vale la empresa
Resumen
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 18 de septiembre de 2026 with claude-haiku-4-5 — shared with all users
West sells self-injection systems such as the SmartDose wearable injector to the same biopharma customers looking to move an infused drug into a patient-administered subcutaneous format.
Alteogen's ALT-B4 hyaluronidase is the only validated alternative to Halozyme's rHuPH20 for converting intravenous biologics to subcutaneous injection, and it has taken licensing deals with Merck, AstraZeneca and Novartis that Halozyme was competing for.
Enable's enFuse on-body injector lets pharmaceutical companies move large-volume intravenous drugs to subcutaneous administration without a hyaluronidase, chasing the same partnerships and the same royalty streams as Halozyme.
Ypsomed supplies pharmaceutical companies with autoinjector and pen platforms for self-administered biologics, the same device business Halozyme bought with Antares Pharma.
SHL Medical designs and manufactures autoinjectors for large pharmaceutical partners, competing directly for the device-development and manufacturing contracts that feed Halozyme's specialty product line.
Amphastar's Amphadase is the bovine hyaluronidase that Halozyme's own 10-K names as the competing product to its marketed drug Hylenex.
Balance y Liquidez
Ingresos
$1.66B
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$414M
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
$645M
Patrimonio Neto Total
$49M
Pasivo Total
$2.48B
Ratio de Liquidez
2.71
Cobertura de Intereses
29.41
Deuda/EBITDA
4.53
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$141.68
Precio Actual
$108.56
Margen de Seguridad
+23.4%
Rango de Valor Justo
$92.09 - $191.27
Dispersión entre los métodos de valoración utilizados, no un intervalo de confianza calibrado estadísticamente.
Métodos de Estimación
Métricas de Valoración
Ratio P/E
32.28
ROE
649.2%
Ratio P/B
87.29
P/FCF
15.54
Margen Bruto
82.4%
ROIC
21.1%
Radar de Rentabilidad
Creación de Valor (Ventaja Competitiva)
ROIC
21.1%
WACC
8.4%
ROIC − WACC
+12.7 pp
El ROIC supera el coste del capital: la empresa está creando valor para los accionistas.
Criterios de Análisis Fundamental
Superado (19)
- EPS shows upward trend
- Price CAGR 27.54%
- ROIC 21.1%
- Gross Margin 82.4%
- P/FCF 15.54
- Operating Margin 35.9%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 180.6%
- Revenue Growth 5Y 39.2%
- Analyst Consensus 81% Buy
- PEG Ratio 1.34
- Earnings Quality (OCF/NI) 1.98
- Share Dilution -4.4%
- Piotroski F-Score 5/9
Fallido (7)
- P/B Ratio 87.29
- Debt/Equity ratio
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Earnings Surprise avg -20.7%
- Net Margin Trend 24.9% vs 47.3%
No disponible (1)
- Dividend Payout NaN%
Piotroski F-Score
Señales mixtas: algunas áreas requieren atención
Calidad de los Beneficios
Alta calidad: beneficios respaldados por efectivo
Dilución de Acciones
Recomprando acciones. Favorable para el accionista
Participaciones institucionales
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. | President, CEO & Director | 62 |
| Mr. Mark Snyder Esq. | Executive VP, General Counsel, Chief Compliance Officer & Corporate Secretary | 58 |
| Mr. Darren Snellgrove | Senior VP & CFO | - |
| Mr. Brian Sweeney | Chief Human Resources Officer | 61 |
| Mr. David A. Ramsay MBA | President of Drug Delivery | 60 |
| Dr. Christopher Wahl M.B.A., M.D. | Chief Scientific Officer | - |
| Dr. Charles P. Theuer M.D., Ph.D. | Chief Medical Officer | 61 |
| Mr. Paul Spence | Chief Commercial Officer | 56 |
| Mr. Rhys de Callier | Chief Strategy Officer | - |
| Mr. Chase Coffman Ph.D. | President of Hypercon | - |
Riesgo de Auditoría
3
Riesgo del Consejo
1
Riesgo de Compensación
4
Riesgo de Derechos del Accionista
3
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Documentos
- Ver documento
Informe anual (10-K)
Un resumen anual del negocio, los resultados financieros y los riesgos de la empresa.
Presentado el 2026-02-17
- Ver documento
Informe trimestral (10-Q)
Una actualización del desempeño financiero de los últimos tres meses.
Presentado el 2026-08-06
- Ver documento
Informe de hecho relevante (8-K)
Un aviso sobre un hecho relevante, como un cambio de dirección o un anuncio importante.
Presentado el 2026-09-30
via SEC EDGAR
Historial de Resultados
via SEC EDGAR
Latest News
Recent headlines for HALO, sourced from Markets Gazette.